Valuation and Risks. Our Buy rating and $5 price target on Rezolute are based on 5.5x our 2036 discounted risk-adjusted revenue estimate of $99.2M. We adjust each pipeline asset for the probability of success (PoS): RZ358 for congenital hyperinsulinism (CHI) at 40%, given the strength of the RIZE data; 60% for Tumor HI, as the program is in the Phase 3 stage.